Here we demonstrated for the first time that molecular remission is an independent predictor of PFS. The retrospective nature and the small sample size are intrinsic limitations, whereas the selection of patients homogeneously treated with fixed duration CIT, mostly frontline, represents the strength of this study.
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study
Arcaini, Luca;
2023-01-01
Abstract
Here we demonstrated for the first time that molecular remission is an independent predictor of PFS. The retrospective nature and the small sample size are intrinsic limitations, whereas the selection of patients homogeneously treated with fixed duration CIT, mostly frontline, represents the strength of this study.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
